Research Reports | Market Assessment
April 2016

Migraine | Unmet Need | US/EU | 2016

For migraine patients who suffer from 15 or more migraine days per month (chronic migraine) and/or those patients who suffer from long-lasting migraine attacks or do not experience sufficient relief with acute therapies, the greatest unmet need in migraine is for migraine prophylactic therapies with improved efficacy and tolerability than currently available therapies. Migraine prophylaxis was not the initial target of development for these therapies, resulting in drugs with sub-optimal efficacy, often only reducing migraine days by one or two days per month, and unfavorable side effects in a population that is generally otherwise healthy. Even in the highly genericized migraine prophylactic market, opportunity exists for branded therapies that offer greater efficacy and tolerability than currently available options.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports